ICEC0942, an Orally Bioavailable Selective Inhibitor of CDK7 for Cancer Treatment.

Patel, Hetal

ICEC0942, an Orally Bioavailable Selective Inhibitor of CDK7 for Cancer Treatment. [electronic resource] - Molecular cancer therapeutics 06 2018 - 1156-1166 p. digital

Publication Type: Journal Article; Research Support, Non-U.S. Gov't

1538-8514

10.1158/1535-7163.MCT-16-0847 doi


Administration, Oral
Animals
Antineoplastic Agents--administration & dosage
Biological Availability
Caspases--metabolism
Cell Cycle--drug effects
Cell Line, Tumor
Cyclin-Dependent Kinases--antagonists & inhibitors
Disease Models, Animal
Dose-Response Relationship, Drug
Humans
Mice
Phosphorylation
Protein Kinase Inhibitors--administration & dosage
Xenograft Model Antitumor Assays
Cyclin-Dependent Kinase-Activating Kinase